title: [Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment].
abstract: OBJECTIVE
  To compare efficacy and safety of warfarin and enoxaparin used in the first month of treatment of patients with an episode of deep vein thrombosis (DVT) and/or pulmonary artery thromboembolism (PATE).
  
  
  METHODS
  Sixty patients (34 males, 26 females, age 18-76 years) after the DVT/PATE episode were divided into two groups. Patients of group 1 received standard therapy (non-fractionated heparin -NFH followed by warfarin), patients of group 2 instead of NFH received enoxaparin (1 mg/kg each 12 hours for at least 30 days). Ultrasonic scanning of the limbs and determination of D-dimer were conducted before and after 1 month of treatment. End points were the following: recurrent DVT/PATE, death due to PATE, hemorrhagic complications.
  
  
  RESULTS
  Improvement of deep vein patency after 1 month of anticoagulant treatment was observed in both the groups. Enoxaparin proved more effective in relation to reduction of the number of venous occlusions (9 and 50, respectively, after 1 month treatment (p < 0.001). Hemorrhagic complications were seen in both the groups with equal frequency (13.4%). These hemorrhagic episodes did not require discontinuation of the drugs. Baseline D-dimer was significantly higher in the enoxaparin group--1.51 (0.73-2.44) mcg/ml vs 0.93 (0.42-1.33) mcg/ml (p = 0.019). After treatment D-dimer level and number of patients with high D-dimer diminished in both groups.
  
  
  CONCLUSIONS
  Enoxaparin proved more effective than warfarin in the first treatment month. In the same safety and prophylactic effect enoxaparin is more effective in recanalization of occusions in the deep veins.
authors.forename: N M
authors.initials: NM
authors.lastname: Vorob'eva
authors.forename: E P
authors.initials: EP
authors.lastname: Panchenko
authors.forename: A I
authors.initials: AI
authors.lastname: Kirienko
authors.forename: A B
authors.initials: AB
authors.lastname: Dobrovol'skiĭ
authors.forename: E V
authors.initials: EV
authors.lastname: Titaeva
authors.forename: O V
authors.initials: OV
authors.lastname: Ermolina
authors.forename: T V
authors.initials: TV
authors.lastname: Balakhonova
authors.forename: V V
authors.initials: VV
authors.lastname: Andriiashkin
authors.forename: S G
authors.initials: SG
authors.lastname: Leont'ev
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020246:Venous Thrombosis / Q000188:drug therapy*; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D014859:Warfarin